Changhua Mu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Changhua Mu has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Robert Richard Flavell
Department of Radiology and Biomedical Imaging University of California, San Francisco San Francisco California USA
85 shared publications - David Meybin Wilson
Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
84 shared publications - Renuka Sriram
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
84 shared publications - Adam Oskowitz
Division of Vascular and Endovascular Surgery, University of California, San Francisco, San Francisco, California
83 shared publications - Anil Parsram Bidkar
Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA
83 shared publications - Anju Wadhwa
University of California, San Francisco 1 Department of Radiology and Biomedical Imaging San Francisco, California
83 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S14 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S14. Comparison of influx and efflux rates of [89Zr]PEG-DFB4 and [89Zr]PEG-DFB1-TLZ3 conjugates in different subcutaneous tumor models (n = 4, mean ± SD). *Prior published data.6
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S14 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S14. Comparison of influx and efflux rates of [89Zr]PEG-DFB4 and [89Zr]PEG-DFB1-TLZ3 conjugates in different subcutaneous tumor models (n = 4, mean ± SD). *Prior published data.6
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S10. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers in nude mice bearing LTL-545 patient derived xenograft (PDX) of tumors at 96 h postinjection. (n = 4, mean ± SD)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S10. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers in nude mice bearing LTL-545 patient derived xenograft (PDX) of tumors at 96 h postinjection. (n = 4, mean ± SD)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S2. Pilot PET/CT studies in prostate, pancreatic, and colorectal cancer models to measure the enhanced permeability retention effect using [89Zr]PEG-DFB1-TLZ3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S2. Pilot PET/CT studies in prostate, pancreatic, and colorectal cancer models to measure the enhanced permeability retention effect using [89Zr]PEG-DFB1-TLZ3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S13 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S13. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing LTL-610 subcutaneous tumors. (n = 4)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S13 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S13. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing LTL-610 subcutaneous tumors. (n = 4)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S7. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing 22rv1 subcutaneous tumors. (n = 4)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S7. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing 22rv1 subcutaneous tumors. (n = 4)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S19 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S19. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of [89Zr]PEG-DFB1-TLZ3 in nude mice inoculated with 22rv1 cells in the left kidney capsule (red arrow). Yellow arrows indicate metastatic tumor.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S19 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S19. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of [89Zr]PEG-DFB1-TLZ3 in nude mice inoculated with 22rv1 cells in the left kidney capsule (red arrow). Yellow arrows indicate metastatic tumor.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S5. Region of interest analysis data reported as %ID/cc of the [89Zr]PEG-DFB1-TLZ3 on on different subcutaneous tumors from Day 1-4 post injection. (n = 4)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S5. Region of interest analysis data reported as %ID/cc of the [89Zr]PEG-DFB1-TLZ3 on on different subcutaneous tumors from Day 1-4 post injection. (n = 4)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S23 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S23. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ of 89Zr labeled nanocarriers in nude mice inoculated with 22rv1 cells via intracardiac injection at 72 h postinjection. (n = 4, mean ± SD)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S23 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S23. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ of 89Zr labeled nanocarriers in nude mice inoculated with 22rv1 cells via intracardiac injection at 72 h postinjection. (n = 4, mean ± SD)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S15 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S15. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 96 h in metastatic mice model with 22rv1 cell inoculated in kidney capsule tumors. (n = 4)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S15 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S15. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 96 h in metastatic mice model with 22rv1 cell inoculated in kidney capsule tumors. (n = 4)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S11. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing LTL-545 subcutaneous tumors. (n = 4)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S11. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing LTL-545 subcutaneous tumors. (n = 4)